phase I study to evaluate pharmacokinetics, pharmacodynamics and safety of emapalumab in Japanese healthy volunteers.
Phase 1
- Conditions
- Hemophagocytic Lymphohistiocytosis
- Registration Number
- JPRN-jRCT2031200446
- Lead Sponsor
- Shimizu Yasuko
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 8
Inclusion Criteria
Healthy volunteers, age between 20 to 50 (inclusive)
Exclusion Criteria
Any clinically significant abnormality in the results of the safety laboratory tests. Subjects presenting a minor deviation from laboratory ranges could be enrolled if the investigator judge it to be non-clinically significant.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method